RhumbLine Advisers
ORKA

RhumbLine Advisers’s Oruka Therapeutics ORKA Stock Holding History

RhumbLine Advisers’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78M Buy
60,784
+14,428
+31% +$961K ﹤0.01% 1398
2026
Q1 		$2.27M Buy
46,356
+5,339
+13% +$186K ﹤0.01% 1777
2025
Q4 		$1.24M Buy
41,017
+10,690
+35% +$298K ﹤0.01% 2120
2025
Q3 		$583K Buy
30,327
+1,757
+6% +$26K ﹤0.01% 2586
2025
Q2 		$320K Buy
+28,570
New +$298K ﹤0.01% 2946

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RhumbLine Advisers's ORKA Position: Q2 2026 in Review

RhumbLine Advisers increased its Oruka Therapeutics (ORKA) stake by 31% in Q2 2026, buying an estimated $961K and bringing the position to 60,784 shares worth $5.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1398.

RhumbLine Advisers first reported a position in ORKA in Q2 2025 and has held it in 5 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • RhumbLine Advisers held 60,784 shares of Oruka Therapeutics worth $5.78M as of Q2 2026.
  • RhumbLine Advisers bought 14,428 Oruka Therapeutics shares in Q2 2026, an estimated $961K.
  • Oruka Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1398 holding.
  • RhumbLine Advisers first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.